1. Home
  2. LYRA vs WNW Comparison

LYRA vs WNW Comparison

Compare LYRA & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • WNW
  • Stock Information
  • Founded
  • LYRA 2005
  • WNW 2015
  • Country
  • LYRA United States
  • WNW China
  • Employees
  • LYRA N/A
  • WNW N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • WNW Catalog/Specialty Distribution
  • Sector
  • LYRA Health Care
  • WNW Consumer Discretionary
  • Exchange
  • LYRA Nasdaq
  • WNW Nasdaq
  • Market Cap
  • LYRA 11.8M
  • WNW 10.1M
  • IPO Year
  • LYRA 2020
  • WNW 2020
  • Fundamental
  • Price
  • LYRA $0.12
  • WNW $1.61
  • Analyst Decision
  • LYRA Hold
  • WNW
  • Analyst Count
  • LYRA 4
  • WNW 0
  • Target Price
  • LYRA $1.25
  • WNW N/A
  • AVG Volume (30 Days)
  • LYRA 828.8K
  • WNW 868.2K
  • Earning Date
  • LYRA 03-13-2025
  • WNW 11-15-2024
  • Dividend Yield
  • LYRA N/A
  • WNW N/A
  • EPS Growth
  • LYRA N/A
  • WNW N/A
  • EPS
  • LYRA N/A
  • WNW N/A
  • Revenue
  • LYRA $1,534,000.00
  • WNW $380,345.00
  • Revenue This Year
  • LYRA N/A
  • WNW N/A
  • Revenue Next Year
  • LYRA $519.89
  • WNW N/A
  • P/E Ratio
  • LYRA N/A
  • WNW N/A
  • Revenue Growth
  • LYRA N/A
  • WNW N/A
  • 52 Week Low
  • LYRA $0.12
  • WNW $1.53
  • 52 Week High
  • LYRA $6.29
  • WNW $70.00
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 23.27
  • WNW 27.15
  • Support Level
  • LYRA $0.14
  • WNW $2.70
  • Resistance Level
  • LYRA $0.20
  • WNW $3.33
  • Average True Range (ATR)
  • LYRA 0.01
  • WNW 0.28
  • MACD
  • LYRA -0.00
  • WNW 0.18
  • Stochastic Oscillator
  • LYRA 1.05
  • WNW 4.43

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.

Share on Social Networks: